Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Located at Chestnut Run Innovation & Science Park, the Merck Wilmington Biotech project will comprise laboratory, ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Last year, Keytruda generated ... approved a $30.2 million grant to Merck, contingent on the company’s decision to set up operations at the Chestnut Run Innovation & Science Park (CRISP ...

A groundbreaking ceremony was held at Chestnut Run Innovation & Science Park on April 29, bringing together business and government officials to celebrate the milestone. Merck’s facility ...

The site will also have the capability to manufacture KEYTRUDA ® (pembrolizumab), and ... Davis, chairman and chief executive officer, Merck. The new facility, located at Chestnut Run Innovation & ...